The U.S. heparin market is likely to gain substantial momentum over the coming years owing to the increasing incidences of venous thromboembolism and genetic risk factors among the population. Heparin is known as an essential anticoagulant and is mainly used to prevent and treat blood clots which are caused by specific medical procedures or conditions.

Heparin is an extremely sulfated glycosaminoglycan and the most negatively charged biological molecule ever known. Heparin further aid to keep the blood flowing smoothly into the body by making a specific natural substance in the body known as anti-clotting protein.

In addition, heparin is also utilized to produce an anti-clotting surface inside numerous medical devices like test tubes, renal dialysis machines among others. According to the data published in the Centers for Disease Control and Prevention, approximately 900,000 people in U.S. are affected by pulmonary embolism and deep vein thrombosis. Further estimates suggest that around 60,000-100,000 Americans die of DVT/PE. This factor is anticipated to propel the regional demand in the forthcoming years.

The U.S. heparin market is segmented in terms of product, application, and distribution channel.

With respect to product, the U.S. heparin market is classified into unfractionated heparin and low molecular weight heparin. Among these products, unfractionated heparin segment accounted for a revenue share of approximately $87.7 million. UFH or unfractionated heparin is essentially a fast-acting blood thinner that works with antithrombin, known to be a natural protein in the human body for blocking the clot formation.

The segment is likely to witness lucrative growth over the coming years since it is inexpensive in comparison to other heparin formulations. UFH swiftly enters the blood stream and acts rapidly to stop formation of clots. It also wears off when the injections or infusion are stopped. These factors are thus likely to contribute towards segmental growth in the coming years.

In terms of application, the overall U.S. heparin market is categorized into coronary artery disease, venous thromboembolism, atrial fibrillation/flutter, and others. Among these, venous thromboembolism segment will witness considerable growth over the coming years. In 2019, the segment accounted for a market share of over 52.6%. UFH is being substituted by low-molecular-weight heparin as the most essential anticoagulant of choice for the initial treatment of patients with venous thromboembolism.

Based on distribution channel, the overall U.S. heparin market is bifurcated into online pharmacy, retail pharmacy, and hospital pharmacy. Among these, the hospital pharmacy segment will exhibit a market growth of more than 6.8% CAGR through the analysis timeframe.